Equities

BlackRock Health Sciences Term Trust

BlackRock Health Sciences Term Trust

Actions
FinancialsClosed End Investments
  • Price (USD)15.26
  • Today's Change0.12 / 0.79%
  • Shares traded310.78k
  • 1 Year change+10.58%
  • Beta0.9143
Data delayed at least 15 minutes, as of Nov 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BlackRock Health Sciences Term Trust (the Trust) is a closed-end management investment trust. The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. The Trust invests at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Trust may also invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. The Trust focuses on small and mid-sized healthcare companies. The Trust invests in industries, such as biotechnology, life sciences tools and services, pharmaceuticals, diversified financial services, health care technology, and others. The Trust’s investment adviser is BlackRock Advisors, LLC.

  • Revenue in USD (TTM)14.44m
  • Net income in USD-22.65m
  • Incorporated2019
  • Employees--
  • Location
    BlackRock Health Sciences Term Trust100 Bellevue ParkwayWILMINGTON 19809United StatesUSA
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
P10 Inc274.50m12.34m1.54bn252.00135.814.3338.915.610.10150.10152.303.190.3284--9.571,089,290.001.442.441.752.90----4.409.69--2.190.4477--21.8748.87-124.42--113.27--
SRH Total Return Fund Inc-100.00bn-100.00bn1.58bn0.00------------------------------------------------------------
NeuroMind AI Corp0.00-1.20m1.60bn-----------0.1844-0.18440.00-0.71150.00-------68.09--------------------------24.71------
BlackRock Health Sciences Term Trust14.44m-22.65m1.63bn----0.8692--112.59-0.2198-0.21980.136517.560.0071--1.43---1.11---1.12---65.26---156.92-----1.130.00001--42.99--110.23------
BlackRock Science and Technolgy Trm Trst99.59m212.27m1.63bn--7.660.9388--16.362.802.801.3222.820.057--24.30--12.15--12.22--77.63--213.13------0.0174---142.72--120.95------
Blackrock Enhanced Equity Dividend Trust49.09m191.73m1.64bn0.008.570.9669--33.481.031.030.2649.130.0285--92.65--11.15--11.31--72.98--390.58------0.0001--7.01--306.31------
Nuveen California Quality Muncpl IncmFnd135.13m153.28m1.65bn--10.770.8945--12.221.061.060.933712.760.0441--2.48--5.000.71195.040.71746.0663.73113.4318.17----0.4001350.923.57-2.03138.8211.79---7.30
Eaton Vance Tax-Mngd Buy-Wrt Opport Fund20.94m255.42m1.65bn--6.470.9935--78.952.192.190.179414.250.0128--6.06--15.667.9715.737.9922.6629.081,219.75561.99----0.0092.69-2.154.07186.61-----3.06
Virtus Investment Partners Inc888.04m119.29m1.70bn824.0014.711.917.661.9116.4516.45122.38126.710.2411--8.101,077,721.004.114.134.614.61----17.0618.99----0.687329.21-4.648.8911.1314.22-5.5228.84
BlackRock Capital Allocation Term Trust81.13m208.42m1.73bn--8.290.9156--21.341.941.940.757317.600.0387--7.08--9.95--11.00--71.44--256.90------0.00---3.48--163.48------
BlackRock ESG Capital Allocatin Trm Trst61.68m260.77m1.74bn--6.530.9091--28.182.612.610.624418.760.0303--25.54--12.79--13.83--62.50--422.80------0.0035--38.89--194.26------
Wisdomtree Inc407.88m46.76m1.75bn314.0042.144.6829.204.300.28480.28482.572.570.4138--10.061,346,152.005.933.246.533.59----14.3310.67--10.510.595870.9915.834.95111.3921.0199.82-5.59
Tri-Continental Corp67.10m253.08m1.76bn--7.031.04--26.164.824.821.2833.370.0398--4.85--15.0210.6715.0510.6989.6288.89377.16287.45----0.0065.97-1.631.83186.61-----2.37
BlackRock Innovation and Growth Trm Trst5.84m-65.77m1.76bn----0.9292--302.09-0.2935-0.29350.02628.460.0028--8.49---3.19---3.23---336.63---1,126.40-----0.54470.0135--26.47--112.77------
Umbra Companies Inc0.00-470.21k1.77bn0.00--1.74-----0.9752-0.97520.002.030.00-------28.19-105.74-35.72-132.77-----------13.360.1835-------5,222.31------
Data as of Nov 23 2024. Currency figures normalised to BlackRock Health Sciences Term Trust's reporting currency: US Dollar USD

Institutional shareholders

34.29%Per cent of shares held by top holders
HolderShares% Held
Saba Capital Management LPas of 16 Oct 202420.75m19.98%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 20242.75m2.65%
RiverNorth Capital Management LLCas of 30 Sep 20241.76m1.70%
Sessa Capital IM LPas of 30 Sep 20241.65m1.59%
Sit Investment Associates, Inc.as of 30 Sep 20241.60m1.54%
Invesco Capital Management LLCas of 30 Sep 20241.53m1.48%
Almitas Capital LLCas of 30 Sep 20241.50m1.45%
Karpus Management, Inc.as of 30 Sep 20241.46m1.41%
UBS Financial Services, Inc.as of 30 Sep 20241.38m1.33%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Sep 20241.22m1.18%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.